Sign In
Buy ADC
$72.03
-0.650 (-0.89%)
At Close: Jun 03, 2026
Agree Realty (ADC) Q4 FFO and Revenues Top Estimates
06:25pm, Tuesday, 10'th Feb 2026
Agree Realty (ADC) came out with quarterly funds from operations (FFO) of $1.11 per share, beating the Zacks Consensus Estimate of $1.1 per share. This compares to FFO of $1.04 per share a year ago.
Agree Realty Corporation Reports Fourth Quarter and Full Year 2025 Results
04:05pm, Tuesday, 10'th Feb 2026
ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced results for the quarter and full year ended December 31, 2025. All per share amounts include
Defence Therapeutics Aligns Accum ADC Strategy Through Multidisciplinary Scientific Advisory Board
03:15am, Tuesday, 10'th Feb 2026
Montreal, Quebec--(Newsfile Corp. - February 10, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision int
F5: Security Incident Impact And Outlook
03:18am, Saturday, 07'th Feb 2026
F5 leverages high-performance ADC products, robust software growth, and partnerships like NVIDIA to capitalize on AI and hybrid multi-cloud trends. Despite the FY25 cybersecurity breach, F5's recurrin
Why Agree Realty Guided Lower for 2026, Despite a Strong Balance Sheet
04:47pm, Friday, 06'th Feb 2026
I spent most of last month pulling apart net lease credit structures — Realty Income's A- rating, NNN REIT's longer-dated debt stack, the mechanics of how buffer distance from the BBB- cliff transla
Agree Realty: Planting Seeds Today To Live In The Shade Tomorrow
11:09am, Friday, 06'th Feb 2026
Agree Realty stands out among net lease REITs for its disciplined low-leverage strategy and focus on high-quality national tenants. ADC's innovative ground lease platform and creative portfolio manage
Agree Realty Declares Monthly Common and Preferred Dividends
04:05pm, Thursday, 05'th Feb 2026
ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash div
DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo
07:00am, Wednesday, 04'th Feb 2026
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
04:05pm, Monday, 02'nd Feb 2026
LAUSANNE, Switzerland, Feb. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced tha
Agree Realty: 4.3% Yield With Rent Recapture Catalyst
06:09pm, Tuesday, 27'th Jan 2026
Agree Realty is positioned for future outperformance after recent underperformance, driven by conservative leverage and high-quality assets. ADC's 67% investment-grade tenant base, focus on freestandi
Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors
08:45am, Monday, 26'th Jan 2026
Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages Akari's proprietary PH1 spliceosome payload and a novel antibody construct t
Agree Realty Corporation $ADC Shares Bought by Strs Ohio
06:12am, Monday, 26'th Jan 2026
Strs Ohio raised its stake in shares of Agree Realty Corporation (NYSE: ADC) by 79.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The
3 Monthly Dividend Payers I'm Buying Right Now
05:09pm, Friday, 23'rd Jan 2026
3 Monthly Dividend Payers I'm Buying Right Now
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
10:00am, Thursday, 22'nd Jan 2026
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are advi
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
04:37pm, Tuesday, 20'th Jan 2026
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC Therapeutics” or the “Company”) (NYSE: ADCT). Such in
